Literature DB >> 7975265

A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein.

J L Brokaw1, C L Yee, K Münger.   

Abstract

The human papillomavirus type 16 (HPV-16) E7 oncoprotein shares structural and functional similarity with the adenovirus (Ad) E1A protein and the SV40 large tumor antigen (TAg). Like these other DNA tumor virus oncoproteins, HPV-16 E7 interacts with the "pocket proteins," a family of host cellular proteins that include the retinoblastoma tumor suppressor protein and can cooperate with the ras oncogene to transform primary rodent cells. Mutational analyses have indicated that amino acid sequences outside of the pRB binding region are also important for the cellular transformation property of HPV-16 E7. These sequences include an amino terminal domain of the E7 protein that is similar to a portion of conserved region 1 of Ad E1A. In this study it is shown that the homologous amino acid sequences in Ad E1A and SV40 TAg are functionally interchangeable with the amino terminal HPV-16 E7 domain in transformation assays. Deletion analysis across the amino terminus of HPV-16 E7 indicated that the overall integrity of the entire CR1 homology domain is important for the biological activity of the HPV E7 oncoprotein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975265     DOI: 10.1006/viro.1994.1688

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.

Authors:  S L Gonzalez; M Stremlau; X He; J R Basile; K Münger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Expression of an E1A/E7 chimeric protein sensitizes tumor cells to killing by activated macrophages but not NK cells.

Authors:  Tanya A Miura; Han Li; Kristin Morris; Sharon Ryan; Kristine Hembre; James L Cook; John M Routes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity.

Authors:  M N Ruesch; L A Laimins
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms.

Authors:  John M Routes; Kristin Morris; Misoo C Ellison; Sharon Ryan
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7.

Authors:  Anita Szalmás; Vjekoslav Tomaić; Om Basukala; Paola Massimi; Suruchi Mittal; József Kónya; Lawrence Banks
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

6.  Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein.

Authors:  D L Jones; K Münger
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 7.  Biology of human papillomaviruses.

Authors:  H R McMurray; D Nguyen; T F Westbrook; D J McAnce
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

8.  Near-infrared Raman Microspectroscopy Detects High-risk Human Papillomaviruses.

Authors:  Elizabeth Vargis; Yi-Wei Tang; Dineo Khabele; Anita Mahadevan-Jansen
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

Review 9.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

10.  E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures.

Authors:  Rui Jorge Nobre; Elsa Herráez-Hernández; Jian-Wei Fei; Lutz Langbein; Sylvia Kaden; Hermann-Josef Gröne; Ethel-Michele de Villiers
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.